This study is collecting information to determine if there is a genetic factor contributing to the development of Parkinson's disease. Adults with Parkinson's disease or individuals that have family members with Parkinson's disease may qualify to participate in this study. All participants that qualify to enroll will have their medical history recorded, a brief neurological examination will be performed and blood will be drawn for genetic analysis. All information collected will be coded to protect participants privacy. No other procedures are involved in this study because it is not a treatment study.
Transcranial direct current stimulation (tDCS) has shown the potential to improve symptoms in patients with movement deficits, such as Parkinson's disease and chronic stroke. However, the effects of tDCS have so far not been proven on a wider scale due to lack of knowledge regarding exactly how tDCS works. This has limited the adoption of this potentially useful therapy for patients with Parkinson's disease, chronic stroke and other conditions affecting movement. We think that by studying the effect of tDCS on brain signals while subjects perform a virtual reality task that requires integration of visual and motor information we can separate out exactly what occurs in the brain when tDCS is turned on. We expect this approach to broaden our understanding of tDCS application in conditions affecting movement and possibly lead to therapeutic advances in this population.
This registry is designed for patients with Parkinson's Disease (PD) who are being considered for treatment with deep brain stimulation (DBS). A registry is a type of observational study that collects information about patients' medical conditions and/or treatments to better understand how a condition or treatment affects patients in the real world.The purpose of the research is to create a list of patients with Parkinson Disease who are all receiving DBS to learn more about the effects of DBS on their PD symptoms
IPX203 is an investigational extended-release (i.e. releases drug more slowly) capsule formulation of carbidopa-levodopa (CD-LD) administered orally (by mouth). "Investigational" means that IPX203 is being tested and has not been approved for marketing.
IPX203 is being investigated to determine whether the drug is safe and potentially has a better effect than currently approved IR CD-LD. If successful, the drug could possibly improve the daily control of motor symptoms in people with Parkinson's disease.
IPX203 is provided as a capsule containing 140 mg LD and 35 mg CD. The study doctor may adjust the IPX203 dosing regimen based on your response to the study drug during the 4 week dose conversion period. Your study doctor will instruct you on the dose of IPX203 or IPX203 placebo that you will receive during the 13-week portion of the study.
Your total participation time in the study will be approximately 24 weeks (6 months), which includes 4 weeks for your initial assessment (screening) period to determine if the trial is suitable for you.
Study I7S-MC-HBEH (HBEH) is a multicenter, randomized (i.e. study in which people are assigned at random (by chance alone) to receive one of several clinical interventions), double-blind (i.e., neither the participant nor the person evaluating for the study knows what group the participant has been assigned to), parallel-group (i.e., a type of study where two groups of treatments, A and B, are given so that one group receives only A while another group receives only B.), placebo-controlled (i.e. one group will receive the study drug and the other will receive a substance that has no therapeutic effect, also known as placebo), fixed-dosage (i.e., the dosage will not change during the course of the study), Phase 2a study (i.e., a trial with the objective of assessing what dose is more effective in treating symptoms.) comparing various dosages of LY3154207 administered orally once a day with placebo over 12 weeks in subjects with mild-to-moderate Parkinson disease dementia (PDD).
The study includes a Screening Period (Visits 1 to 2) of a minimum of 7 days and up to 14 days, a 14-day Pretreatment Period (Visits 2 to 3), a 12-week Treatment Period (Visits 3 to 11), and a 14-day Safety Follow-Up Period (Visit 12).
Your participation will last about 17-18 weeks.
The purpose of this study is to find out how LY3154207 compares with placebo in treating memory and thinking problems in individuals with mild-to-moderate Parkinson's disease dementia.
Candidates for this study may or may not report disturbances in odor perception as their primary reason for seeking treatment at MUSC. This study is designed to collect long term, observational data from patients who are being treated with routine clinical care in health clinics at MUSC. Data from clinical questionnaires will be de-identified and stored in a database.
Transcranial direct current stimulation (tDCS) has shown the potential to improve symptoms in patients with motor deficits, however its effects have not been consistent in randomized studies to date, limiting widespread adoption of this technology. A critical gap in our knowledge is a detailed understanding of how tDCS affects motor areas in the brain. We propose using tDCS while recording directly from motor cortex using subdural electrocorticography (sECoG) in patients undergoing deep brain stimulation surgery. We expect this novel approach to broaden our understanding of tDCS application and possibly lead to therapeutic advances in this population.
An investigator initiated pilot study of transcutaneous auricular vagal nerve stimulation (taVNS) in mild to moderate Parkinson's disease (PD).
We will assess whether nerve stimulation done on the surface of the skin, (called transcutaneous vagus nerve stimulation (taVNS)) is safe and effective in people with Parkinson's Disease (PD). A small electrical stimulator will be used to deliver electric pulses to a small portion of the left ear of the study participants. Participants will be assigned by chance to either 2 weeks of treatment with real taVNS, or a sham stimulation. The investigator will rate PD motor and cognitive symptoms before, during, and after the 2-week cycle. The investigators will also perform a number of blood and eye movement tests to check for the effectiveness of the stimulation, and perform regular safety checks.
The purpose of this research is to determine how to measure the severity of freezing of gait and its relationship to certain brain structures. Testing to assess Parkison's motor symptoms, and gait assessment in the motion analysis laboratory will be performed at each visit in conjunction with patient's self assessment questionnaires regarding their gait.
This is an exploratory study and the information obtained may lead to new findings regarding the inflammatory and neurodegenerative mechanisms in the progression of PD and help to develop new drugs to halt the disease progression. The study simply involves a one time blood draw.